PMID- 27153853
OWN - NLM
STAT- MEDLINE
DCOM- 20170215
LR  - 20181113
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 37
IP  - 8
DP  - 2016 Aug
TI  - Crosstalk between TGF-beta signaling and miRNAs in breast cancer metastasis.
PG  - 10011-9
LID - 10.1007/s13277-016-5060-8 [doi]
AB  - Transforming growth factor-beta (TGF-beta) signaling pathway is a key regulator of 
      various cancer biologies, including cancer cell migration, invasion, 
      angiogenesis, proliferation, as well as apoptosis, and it is one of indispensable 
      signaling pathways during cancer metastasis. TGF-beta signaling pathway can regulate 
      and be regulated by a series of molecular and signaling pathways where microRNAs 
      (miRNAs) seem to play important roles. miRNAs are small non-coding RNAs that can 
      regulate expressions of their target genes. Emerging evidence suggest that miRNAs 
      participate in various biological and pathologic processes such as cancer cells 
      apoptosis, proliferation, invasion, migration, and metastasis by influencing 
      multiple signaling pathways. In this article, we focus on the interaction between 
      miRNAs and TGF-beta in breast cancer (BC) metastasis through modulating 
      invasion-metastasis-related factors, including epithelial-to-mesenchymal 
      transition (EMT), cancer stem cells (CSCs), matrix metalloproteinase (MMP), 
      tissue inhibitors of MMPs (TIMPs), cell adhesion molecules (CAMs), and tumor 
      microenvironment (TME). Through a clear understanding of the complicated links 
      between TGF-beta pathway and miRNAs, it may provide a novel and safer therapeutic 
      target to prevent BC metastasis.
FAU - Chen, Wei
AU  - Chen W
AD  - Xuzhou Medical College, Xuzhou, Jiangsu, China.
FAU - Zhou, Siying
AU  - Zhou S
AD  - Department of General Surgery, Jiangsu Cancer Hospital Affiliated to Nanjing 
      Medical University, Nanjing, Jiangsu, China.
AD  - The First Clinical Medical College, Nanjing University of Chinese Medicine, 
      Nanjing, Jiangsu, China.
FAU - Mao, Ling
AU  - Mao L
AD  - Department of General Surgery, Huaian Second People's Hospital, Huaian, China.
FAU - Zhang, Heda
AU  - Zhang H
AD  - Xuzhou Medical College, Xuzhou, Jiangsu, China.
AD  - Department of General Surgery, Jiangsu Cancer Hospital Affiliated to Nanjing 
      Medical University, Nanjing, Jiangsu, China.
FAU - Sun, Dawei
AU  - Sun D
AD  - Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Cancer 
      Institute of Jiangsu Province, 42 Bai Zi Ting Road, Nanjing, Jiangsu, 210000, 
      China.
FAU - Zhang, Junying
AU  - Zhang J
AD  - Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Cancer 
      Institute of Jiangsu Province, 42 Bai Zi Ting Road, Nanjing, Jiangsu, 210000, 
      China.
FAU - Li, JIan
AU  - Li J
AD  - Department of General Surgery, Jiangsu Cancer Hospital Affiliated to Nanjing 
      Medical University, Nanjing, Jiangsu, China.
FAU - Tang, Jin-Hai
AU  - Tang JH
AD  - Xuzhou Medical College, Xuzhou, Jiangsu, China. jhtang_professor@126.com.
AD  - Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Cancer 
      Institute of Jiangsu Province, 42 Bai Zi Ting Road, Nanjing, Jiangsu, 210000, 
      China. jhtang_professor@126.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160506
PL  - Netherlands
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental 
      Biology and Medicine
JID - 8409922
RN  - 0 (Antineoplastic Agents)
RN  - 0 (MicroRNAs)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Tissue Inhibitor of Metalloproteinases)
RN  - 0 (Transforming Growth Factor beta)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
SB  - IM
MH  - Antineoplastic Agents/pharmacology
MH  - Apoptosis
MH  - Breast Neoplasms/drug therapy/genetics/*pathology
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Drug Resistance, Neoplasm
MH  - Epithelial-Mesenchymal Transition/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Matrix Metalloproteinases/physiology
MH  - MicroRNAs/*genetics
MH  - Models, Biological
MH  - Neoplasm Metastasis
MH  - Neoplasm Proteins/*genetics/physiology
MH  - Signal Transduction/*physiology
MH  - Tissue Inhibitor of Metalloproteinases/physiology
MH  - Transforming Growth Factor beta/*physiology
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - Breast cancer
OT  - Metastasis
OT  - TGF-beta pathway
OT  - Therapy
OT  - miRNAs
EDAT- 2016/05/08 06:00
MHDA- 2017/02/16 06:00
CRDT- 2016/05/08 06:00
PHST- 2015/11/28 00:00 [received]
PHST- 2016/05/01 00:00 [accepted]
PHST- 2016/05/08 06:00 [entrez]
PHST- 2016/05/08 06:00 [pubmed]
PHST- 2017/02/16 06:00 [medline]
AID - 10.1007/s13277-016-5060-8 [pii]
AID - 10.1007/s13277-016-5060-8 [doi]
PST - ppublish
SO  - Tumour Biol. 2016 Aug;37(8):10011-9. doi: 10.1007/s13277-016-5060-8. Epub 2016 
      May 6.